InventisBio, a Chinese biotech company focused on small molecule drugs, has raised $147 million in a Series D funding round. The funding round of the clinical stage company was led by Hillhouse Capital affiliate GL Ventures. Other new investors are Qiming Venture Partners, Janchor, Matrix Partner China, AIHC Capital, Dyee Capital, and E Fund Capital […]
In a significant development within the pharmaceutical industry, Shanghai-based InventisBio has entered into a strategic partnership with Betta Pharmaceuticals Co., Ltd. to co-develop the promising lung cancer drug D-0316. Under this agreement, InventisBio has out-licensed the rights to D-0316 in China, Hong Kong, and Taiwan to Betta Pharmaceuticals Co., Ltd. in a deal valued at […]
